TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
CASI Pharmaceuticals ( (CASI) ) has shared an update.
On November 19, 2025, CASI Pharmaceuticals announced a significant change in its board governance with the appointment of James Huang as the Non-Executive Chairman of the Board, effective November 17, 2025. This move is part of a strategic effort to enhance governance and drive growth, as Dr. Wei-Wu He steps down from the Executive Chairman role but remains on the board. The appointment reflects confidence in Huang’s vision and leadership as the company advances its CID-103 development, particularly in addressing organ transplant rejection. This governance change is expected to align with shareholder interests and sustain the company’s long-term success.
The most recent analyst rating on (CASI) stock is a Hold with a $1.00 price target. To see the full list of analyst forecasts on CASI Pharmaceuticals stock, see the CASI Stock Forecast page.
Spark’s Take on CASI Stock
According to Spark, TipRanks’ AI Analyst, CASI is a Neutral.
CASI Pharmaceuticals’ overall stock score is primarily impacted by its weak financial performance, characterized by declining revenue, high leverage, and negative cash flows. Technical analysis further indicates bearish momentum, while poor valuation metrics reflect the company’s financial difficulties. These factors collectively result in a low overall stock score.
To see Spark’s full report on CASI stock, click here.
More about CASI Pharmaceuticals
CASI Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing CID-103, a potential best-in-class, anti-CD38 monoclonal antibody for patients with organ transplant rejection and autoimmune diseases. The company is actively engaged in clinical trials and has received FDA IND clearance for a Phase 1 study in renal allograft antibody-mediated rejection in the U.S.
Average Trading Volume: 126,915
Technical Sentiment Signal: Sell
Current Market Cap: $18.44M
For a thorough assessment of CASI stock, go to TipRanks’ Stock Analysis page.